Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial.

Abstract

Oral or intravenous methylprednisolone (≥500 mg/day for 5 days) is recommended for multiple sclerosis (MS) relapses. Nonetheless, the optimal dose remains uncertain. We compared clinical and radiological effectiveness, safety and quality of life (QoL) of oral methylprednisolone [1250mg/day (standard high dose)] versus 625mg/day (lesser high dose), both for 3days] in MS relapses. A total of 49 patients with moderate to severe MS relapse within the previous 15days were randomized in a pilot, double-blind, multicentre, non-inferiority trial (ClinicalTrial.gov, NCT01986998). The primary endpoint was non-inferiority of the lesser high dose by Expanded Disability Status Scale (EDSS) score improvement on day 30 (non-inferiority margin, 1 point). The secondary endpoints were EDSS score change on days 7 and 90, changes in T1 gadolinium-enhanced and new/enlarged T2 lesions on days 7 and 30, and safety and QoL results. The primary outcome was achieved [mean (95% confidence interval) EDSS score difference, -0.26 (-0.7 to 0.18) at 30days (P=0.246)]. The standard high dose yielded a superior EDSS score improvement on day 7 (P=0.028). No differences were observed in EDSS score on day 90 (P=0.352) or in the number of T1 gadolinium-enhanced or new/enlarged T2 lesions on day 7 (P=0.401, 0.347) or day 30 (P=0.349, 0.529). Safety and QoL were good at both doses. A lesser high-dose oral methylprednisolone regimen may not be inferior to the standard high dose in terms of clinical and radiological response.